Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — Q2 2025 Earnings Presentation
16 slides from Crinetics Pharmaceuticals's earnings presentation, Aug 7, 2025
Slide 1: Second Quarter 2025 Financial Results and Business Update
August 7, 2025 Second Quarter 2025 Financial Results and Business Update
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Su
Slide 3: Serving Our Patients
Serving Our Patients Our mission is to build the world’s leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. We made a commitment to the acromegaly community And we stand by it Traci Acromegaly Patient CRI
Slide 4: Coming Soon – PDUFA Date September 25, 2025
Coming Soon – PDUFA Date September 25, 2025 4 PALSONIFY (paltusotine) is an investigational drug. Commercial launch of paltusotine is dependent on regulatory approval.
Slide 5: Engaging with Healthcare Professionals Across Multiple Platforms
Engaging with Healthcare Professionals Across Multiple Platforms Increasing Education and Long-Term Data Positively “Coming Soon” Campaign Awareness Received by HCPs Now Live ✓ MSLs in the field visiting endocrinologists ✓ PALSONIFY was well-tolerated and IGF-1 levels remained ✓ Evidence generation
Slide 6: Preparing for a Successful Launch of PALSONIFY
Preparing for a Successful Launch of PALSONIFY Building Strong Foundational Infrastructure ACTIVATE …for paltusotine and the pipeline in the US and globally A D OPT ✓ Field force on board ✓ Productive ongoing engagement with payers A C C ESS ✓ Market research and ad boards with patients, HCPs and pa
Slide 7: Strategies to Address the Significant Unmet Need in the Acromegaly Community
Strategies to Address the Significant Unmet Need in the Acromegaly Community Currently on SRL Reduce burden and improve control Treatment ~11,000 Undertreated Drive treatment to target Addressable US patients Untreated Educate and motivate ~500 Addressable Newly Diagnosed Initiate on innovative trea
Slide 8: Mutli-Channel Approach Driving Patient Awareness
Mutli-Channel Approach Driving Patient Awareness Educating and Empowering to Optimize Success ACROMEGALY REALITY Disease education campaign to raise awareness of the lived realities of acromegaly and support earlier recognition and diagnosis PATIENT ACTIVATION CrinetiCARE Comprehensive patient suppo
Slide 9: Compelling Value Proposition for Paltusotine
Compelling Value Proposition for Paltusotine Faster Disease Control Titration to optimal level in weeks Reduce Treatment Burden Injectable SRLs difficult to administer Maintain Symptom Control Limit breakthrough symptoms Improve Patient Adherence Wendy Once-daily oral dosing Acromegaly Patient PALSO
Slide 10: Continued Value Creation with Deep Pipeline of Transformative Drug Candidates
Continued Value Creation with Deep Pipeline of Transformative Drug Candidates Program IND- Discovery Phase 1 Phase 2 Phase 3 Registration Upcoming Milestones Enabling Acromegaly (US) PDUFA Date (September 2025) Acromegaly (EU) Paltusotine (SST2 agonist) CHMP Opinion (1H 2026) Carcinoid syndrome Phas
Slide 11: Establishing Uncompromising CAH Treatment Goals
Establishing Uncompromising CAH Treatment Goals Androgen and GC Establishing the uncompromising treatment goal of normal adrenal androgens (A4 ≤ULN) Normalization with physiologic glucocorticoid replacement Early and extended period for glucocorticoid reduction designed to achieve GC as Replacement,
Slide 12: Global Phase 2/3 Pediatric CAH Trial Designed to Assess Normalization of Androgens and Glucocorticoids
Global Phase 2/3 Pediatric CAH Trial Designed to Assess Normalization of Androgens and Glucocorticoids Operationally Seamless Phase 2/3 Study Design Part A (Phase 2) Part B (Phase 3) • Open-label, semi-sequential cohorts • Double-blind, Placebo controlled • Dose Determination for Part B • Confirmato
Slide 13: Financial Results
Financial Results Three Months Ended (in millions) June 30, 2025 March 31, 2025 Revenues $ 1.0 $ 0.4 R&D Expenses (80.3) (76.2) SG&A Expenses (49.8) (35.5) Net Loss $ (115.6) $ (96.8) Common Stock Outstanding of 94.2 Million as of 7/29/2025 Fully Diluted Share Count of 111.9 Million as of 7/29/202
Slide 14: $1.2 Billion Cash Balance Funds Current Operating Plan into 2029
$1.2 Billion Cash Balance Funds Current Operating Plan into 2029 $1.2 Billion Supports Strategic Initiatives Including: Cash, cash equivalents, & investments as of June 30, 2025 ➢ Anticipated launch of paltusotine and commercial infrastructure build Into 2029 Cash runway based on current operating p
Slide 15: Building the Premier, Endocrine-Rooted Pharmaceutical Company
Building the Premier, Endocrine-Rooted Pharmaceutical Company First anticipated Deep pipeline with World-class R&D IP rights commercial launch 2 late-stage programs in capabilities, 4 candidates into 2040s this year 4 indications in preclinical $1.2B of cash, cash Extensive internal Corporate dedica
Slide 16: Thank You
| THANK YOU armaceuticals
Crinetics Pharmaceuticals — Q2 2025 Earnings Presentation on 6ix